Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-24-020476

CHIEF SCIENTIFIC OFFICER sold 12,000 shares at an average $26.70 ($320,378)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2024-07-29 Sale : show line 1 in the form 10b5-1 −11,797 $26.69 $314,809 1,093,238 I
2024-07-29 Sale : show line 2 in the form 10b5-1 −203 $27.43 $5,569 1,093,035 I
Open-market sales · 12,000 sh · avg $26.70 · $320,378
Loading xslF345X05/form4-07312024_110752.xml…